Virpax appoints Usama Chaudhry as CFO under independent contractor agreement

Virpax Pharmaceuticals, Inc.

Appointment effective November 18, 2024; Chaudhry to oversee financial reporting, budgeting, compliance.
Annual fee of $180,000 payable in monthly installments; reasonable pre-approved expenses reimbursed.
Chaudhry holds a Bachelor of Commerce in accounting from University of Northern British Columbia.
Agreement is with Chaudhry U Consulting Inc.; Chaudhry remains independent contractor.
Agreement includes 12-month post-termination non-compete and non-solicitation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Usama Chaudhry

Chief Financial Officer

Virpax Pharmaceuticals, Inc.

Effective: 2024-11-18
Filed: November 20, 2024, 6:59 PM ET

On November 18, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) appointed Mr. Usama Chaudhry as Chief Financial Officer of the Company under an Independent Contractor Agreement (the “Agreement”) with Chaudhry U Consulting Inc., a Canadian corporation represented by Mr. Chaudhry.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Usama Chaudhry was appointed as Chief Financial Officer at Virpax Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 18, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) appointed Mr. Usama Chaudhry as Chief Financial Officer of the Company under an Independent Contractor Agreement (the “Agreement”) with Chaudhry U Consulting Inc., a Canadian corporation represented by Mr. Chaudhry.

View on SEC.gov

Source: SEC EDGAR

accession 0001731122-24-001838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.